MedTrace Logo

Effect of TrueTear Corneal Surface Imaging

NCT03637348 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-08-11

Study results available
· View outcomes & findings →

Summary

This study will evaluate the utility of TrueTear™ to improve anterior corneal surface imaging quality before cataract surgery, refractive lens exchange, or laser refractive surgery.

Conditions

  • Cataract
  • Myopia

Interventions

DEVICE

TrueTear

Ues of TrueTear neurostimulator

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Price Vision Group

    lead INDUSTRY

Principal Investigators

  • Francis W Price, Jr., MD · Price Vision Group

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-13
Primary Completion
2019-07-08
Completion
2019-07-08
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03637348 on ClinicalTrials.gov